ZEPHYRTEL
2.4.2019 11:51:04 CEST | Business Wire | Press release
ZephyrTel, a division of ESW Capital dedicated to serving global telecommunications operators, is pleased to announce that it has today signed a telecom-focused Strategic Collaboration Agreement with Amazon Web Services (AWS).
This agreement comes less than a year after ZephyrTel’s formation and is testament to the company’s growth strategy and focus on cloud leadership in the Telco market. The strategic collaboration agreement will initially be focused on a joint go-to market approach based on ZephyrTel’s industry leading Customer Experience Management platform, ResponseTek for Telco, which was the first ZephyrTel solution to be migrated to AWS.
Work is already underway to migrate other ZephyrTel solutions to AWS, including Mobilogy, OASIS Cloud Contact Centre, Volt Delta 360 Directory Assistance, PeerApp and Vasona, as well as NewNet Messaging and the Invigorate Rating and Charging platform which ZephyrTel acquired in December 2018.
ZephyrTel’s Dev Factory is also working with AWS in the Artificial Intelligence (AI) and Machine Learning (ML) space and development is underway on the first suite of predictive analytics applications built on AWS.
Mike Shinya, CEO of ZephyrTel, said, “We are dedicated to partnering with our 330 global Telco Operator customers on their journey to becoming Digital Telcos. We expect our cloud offerings to deliver Total Cost of Ownership savings to our customers of up to 90% and we are thrilled to work with AWS’s dedicated Telecom business to extend our joint offerings.”
“Telecommunication service providers are accelerating their migration to AWS in order to deliver lower total cost of IT for their organizations as well as increase automation of their services and business processes in order to drive agility and innovation for their customers,” said Jean-Philippe Poirault, Vice President and Global Head of Telecom, Amazon Web Services EMEA SARL. “We are excited to support ZephyrTel in delivering cloud-deployable telecom solutions on AWS to enable and accelerate the digital transformation journey of our shared customers.”
The agreement will also see ZephyrTel join the AWS Partner Network (APN) with immediate effect. The APN is a global partner program that helps APN Partners build successful AWS-based businesses or solutions by providing business, technical, marketing, and go-to-market support.
About ZephyrTel
Launched in early 2018, ZephyrTel has rapidly scaled up to reach $70M revenues in a short space of time. ZephyrTel has installations in over 50 countries around the world and its customers include more than 330 of the global leading Telecom Operators. The company has access to over 4000 of the world’s top talented engineers and other skilled professionals, available through affiliated company Crossover for Work’s platform. ZephyrTel is currently serving the telecommunications industry worldwide with software products for retail, infrastructure, mobile, cloud, and customer experience and is continuously extending its telco product range. More information is available at www.zephyrtel.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005511/en/
Contact:
ZephyrTel For further information please email: Mike Shinya, CEO mike.shinya@zephyrtel.com Ali Perkins, Chief Marketing Officer ali.perkins@zephyrtel.com
For media enquiries please email: Paula Elliott, Managing Director, C8 Consulting paula@c8consulting.co.uk
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom